Expertise in
7
conditions

Ming J. Liu

No. 154, Anshan Road, 
Xiaobailou, CN 
Expertise in
7
conditions
No. 154, Anshan Road, 
Xiaobailou, CN 
OverviewLocationsClinical Research

Overview

Ming Liu practices in Xiaobailou, China. Liu is highly rated in 7 conditions, according to our data. Their top areas of expertise are Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), Low Potassium Level, Low Blood Sugar, and Thyroidectomy.

Their clinical research consists of co-authoring 279 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

No. 154, Anshan Road, Xiaobailou, 300052, China
Other Locations
Anshan Road No. 154, P.R, Xiaobailou, 300052, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)
Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes
A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Drug
Study Drugs: Dulaglutide, Insulin Glargine
Study Phase: Phase 3
A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea
A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea
Enrollment Status: Completed
Publish Date: January 06, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Chinese Patients With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Chinese Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

279 Total Publications

Refractory hypercalcemic crisis: A case of primary hyperparathyroidism with Gitelman syndrome.
Refractory hypercalcemic crisis: A case of primary hyperparathyroidism with Gitelman syndrome.
Journal: The Journal of international medical research
Published: December 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
    View All 50 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile